reports time alternative criticism advisory possible meanwhile shelves november shares panel medicines factors withdrawn given cardiovascular explained earnings observed voluntarily said new regulators ruled stomach stopped sales american slide class suggested since recommend caught reintroduction approval inhibitors rung harmful fourth graham also fda shops independent millions litigation facing appear patients information create research unique drugs withdrew days thursday food boost bells merck consider really david pain things us verdict note september hearing names easier aside evidence makes likely battles already months calculations asked tuesday european year cost news market available disease based three stroke risk cautious attack case celebrex people benefits firm office clear safety cause changed whether set companies administration users problems dr showed many products regulator say earlier injured give would move told dollars back least make including high legal giving company called went profits cover risks cox increased knowing similar claim analysts doubled selling vioxx pfizer last presented heart approve fewer brand putting agency body linked gets sale alarm mr rule bn painkillers bextra senate drug head taking doctors place deaths investigations marketed take though may quarter announcement friday justify related peter kim stem still developed sold therapies light caused need decide surprise handling according oversee tumbled